Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2022

View Archived Issues

S100A4 levels correlate with active eosinophilic esophagitis

IL13RA1 is a therapeutic target in the treatment of EoE

New complement factor B inhibitors identified at Shanghai Meiyue Biotech Development

PROTACs targeting IRAK-4 synthesized at Shanghai Leadingtac Pharmaceutical

Kira Pharmaceuticals discovers C5aR antagonists

BeiGene divulges new G12C mutant GTPase KRAS inhibitors

Beijing Tide Pharmaceutical patents son of sevenless homolog 1 inhibitors

Fibulin-2 as a novel therapeutic target in multiple sclerosis

Study finds potential entry points to Huntington's therapy

Targeting MRGPRX2-mediated mast cell activation as a therapeutic strategy for atopic dermatitis

Discovery of novel orally bioavailable inhibitors of EGFR T790M/C797S mutants

ANGPTL4 is elevated in peanut allergy

Tonix enters research agreement with Inserm to study oxytocin in Prader-Willi syndrome mouse model

PBI-0451 shows promising results for the treatment of COVID-19

SpFN_1B-06-PL vaccine induces durable immune response against pathogens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...